Mallinckrodt acquiring Sucampo Pharmaceuticals for $1.2B — 4 insights

Mallinckrodt will acquire Sucampo Pharmaceuticals' commercial and development assets for approximately $1.2 billion, pending regulatory approval.

Here's what you should know:

1. Mallinckrodt expects to report adjusted diluted earnings of at least $0.30 per share in 2018. It expects to double those earnings in 2019, assuming an expected first quarter 2018 close of the acquisition.

2. Mallinckrodt is offering $18 per share to all Sucampo shareholders.

3. Mallinckrodt will acquire two commercial assets and two developmental assets. Specifically, Mallinckrodt is acquiring Amitiza, a chronic idiopathic constipation and irritable bowel syndrome drug and Rescula, a drug for ocular hypertension and open-angle glaucoma.

Concerning developmental assets, Mallinckrodt is acquiring a drug that treats a neurodegenerative disease that affects all ages and a familial adenomatous polyposis treatment. Mallinckrodt will continue to develop both drugs.

4. Mallinckrodt CEO and President Mark Trudeau said, "Mallinckrodt's acquisition of Sucampo is the latest milestone towards our vision of becoming an innovation-driven specialty pharmaceutical growth company focused on improving outcomes for patients with severe and critical conditions."

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast